Molecular-Genetic Monitoring of SARS-CoV-2 Genovariants in the Territory of the Volga Federal District of the Russian Federation. Communication 1

Emergence of various genovariants of the SARS-CoV-2 virus, which are characterized by a higher ability to spread and a more severe clinical manifestations compared to the initial variants, require molecular-genetic monitoring of strains circulating in the Russian Federation.

The aim of the work was to identify the VOC SARS-CoV-2 genovariants in the territory of the Republics of Bashkortostan, Tatarstan, Udmurtia, and Samara, Penza, Saratov, Ulyanovsk, and Orenburg Regions.

Materials and methods. The identification of genovariants and the determination of the type of mutations was carried out by the Sanger fragment sequencing method.

Results and discussion. The study examined 298 samples of clinical material obtained from the Centers for Hygiene and Epidemiology in the Republics of Bashkortostan, Tatarstan, Udmurtia, Samara, Penza, Saratov, Ulyanovsk, and Orenburg Regions. In 17 % of cases, the variability of the SARS-CoV-2 virus was observed for one or more markers: in three samples, a new coronavirus of the B. 1.1.7 line (“British”) was detected; in a number of cases, only one mutation was detected in the virus found in samples – deletion Y144 or substitution D138Y, E484K, N501Y, and very rarely two mutations – deletion Y144 and substitution E484K. The presence of the L141-G142-V143 deletion localized in the recurrent deletion region RDR2 of the S-gene was shown in 10 % of the cases. The data obtained indicate the heterogeneity in macroorganism of the population of the new coronavirus with the deletion L141-G142-V143, which leads to a change in the antigenic structure of the virus, which probably allows the virus to evade the immune response.

1. Bhattacharyya Ch., Das Ch., Ghosh A., Singh A.K., Mukherjee S., Majumder P.P., Basu A., Biswas N.K. Global spread of SARS-CoV-2 subtype with spike protein mutation D614G is shaped by human genomic variations that regulate expression of TMPRSS2 and MX1 genes. bioRxiv. 2020. 05.04.075911. DOI: 10.1101/2020.05.04.075911.

2. Pachetti M., Marini B., Benedetti F., Giudici F., Mauro E., Storici P., Masciovecchio C., Angeletti S., Ciccozzi M., Gallo R.C., Zella D., Ippodrino R. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J. Transl. Med. 2020; 18(1):179. DOI: 10.1186/s12967-020-02344-6.

3. Krasnov Ya.M., Popova A.Yu., Safronov V.A., Fedorov A.V., Badanin D.V., Shcherbakova S.A., Kutyrev V.V. [Genomic diversity analysis of SARS-CoV-2 and epidemiological features of adaptation of COVID-19 agent to human population (Communication 1)]. Problemy Osobo Opasnykh Infektsii [Problems of Particularly Dangerous Infections]. 2020; (3):70–82. DOI: 10.21055/0370-1069-2020-3-70-82.

4. Public Health England. Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01 (2020). (Cited: March 29, 2021). [Internet]. Available from: http://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-ofconcern-20201201.

5. McCarthy K.R., Rennick L.J., Nambulli S., Robinson-McCarthy L.R., Bain W.G., Haidar G., Paul Duprex W. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science. 2021; 371(6534):1139–42. DOI: 10.1126/science.abf6950.